MARKET

ALPMY

ALPMY

Astellas Pharma
OTCPK
15.74
+0.24
+1.55%
Closed 15:50 02/06 EST
OPEN
15.16
PREV CLOSE
15.50
HIGH
15.75
LOW
15.16
VOLUME
11.77K
TURNOVER
180.94K
52 WEEK HIGH
15.87
52 WEEK LOW
8.18
MARKET CAP
28.19B
P/E (TTM)
33.56
1D
5D
1M
3M
1Y
5Y
1D
Goldman Sachs Remains a Buy on Astellas Pharma (ALPMF)
TipRanks · 2d ago
Astellas Pharma (ALPMF) Gets a Hold from Morgan Stanley
TipRanks · 2d ago
Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)
TipRanks · 3d ago
Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
TipRanks · 3d ago
Astellas Pharma ADR GAAP EPS of ¥185.20, revenue of ¥1601.32B; updates full-year forecast
Seeking Alpha · 3d ago
Weekly Report: what happened at ALPMY last week (0126-0130)?
Weekly Report · 5d ago
Daiwa Sticks to Their Sell Rating for Astellas Pharma (ALPMF)
TipRanks · 01/29 10:17
Belite Bio On A Tear As It Approaches Key Regulatory Submissions
Seeking Alpha · 01/27 17:41
More
About ALPMY
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Webull offers Astellas Pharma Inc stock information, including OTCPK: ALPMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALPMY stock methods without spending real money on the virtual paper trading platform.